公开(公告)号：US20160061846A1

公开(公告)日：2016-03-03

申请号：US14935994

申请日：2015-11-09

Applicant: Hitachi, Ltd. ,  National University Corporation Hokkaido University

Inventor： Takeshi SAKAMOTO ,  Hiroko HANZAWA ,  Naomi MANRI ,  Yuji KUGE

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  A61B5/0071 ,  A61B5/02007 ,  A61B5/055 ,  A61B6/504 ,  A61B6/508 ,  A61B8/0891 ,  G01N2800/323 ,  G01N2800/52

Abstract: The present invention provides a method and a means for evaluating atherosclerotic lesions by identifying a protein (marker protein) group, the expression level of which varies according to the progression of the atherosclerotic lesion, and using the proteins. Specifically, the present invention relates to a method for evaluating atherosclerotic lesions, comprising the steps of detecting a marker protein exhibiting an expression pattern (expression variation) characteristic at a specific disease stage of atherosclerotic lesions in a subject, and evaluating the atherosclerotic lesions in the subject based on the detection result.

Abstract translation: 本发明提供了一种通过鉴定其表达水平根据动脉粥样硬化病变的进展以及使用蛋白质而变化的蛋白质（标记蛋白）组来评价动脉粥样硬化病变的方法和手段。 具体而言，本发明涉及评价动脉粥样硬化病变的方法，其特征在于，包括以下步骤：检测在受试者的动脉粥样硬化病变的特定疾病阶段具有特征的表达模式（表达变异）的标记蛋白，并评价动脉粥样硬化病变 主体根据检测结果。

公开(公告)号：US20150105291A1

公开(公告)日：2015-04-16

申请号：US14514523

申请日：2014-10-15

Applicant: HITACHI, LTD.

Inventor： Hiroko HANZAWA ,  Takeshi SAKAMOTO ,  Yuji KUGE

IPC: G01N33/68 ,  G01N33/573

CPC classification number: G01N33/564 ,  A61P9/10 ,  C07K14/472 ,  C07K14/745 ,  C07K16/36 ,  G01N33/50 ,  G01N33/53 ,  G01N2333/4716 ,  G01N2800/324

Abstract: It is intended to evaluate an ischemic heart disease with high accuracy by convenient operation. The method for evaluating an ischemic heart disease according to the present invention comprises the steps of: assaying complement factor H and/or complement factor D in a sample derived from the blood of a test subject; and comparing the concentration of the complement factor H and/or the concentration of the complement factor D assayed in the preceding step with a reference value(s), wherein it is determined that the seriousness of the ischemic heart disease is high when the concentration falls below the reference value.

Abstract translation: 旨在通过方便的操作高精度地评估缺血性心脏病。 根据本发明的用于评估缺血性心脏病的方法包括以下步骤：测定源自测试对象的血液的样品中的补体因子H和/或补体因子D; 并将上述步骤中测定的补体因子H的浓度和/或补体因子D的浓度与参考值进行比较，其中确定当浓度下降时缺血性心脏病的严重性高 低于参考值。